Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration

• Published in: Clinical Kidney Journal 2023, Vol.16 (11), p.2254
• Main Authors: de Sequera, Patricia, Perez-Garcia, Rafael, Vega, Almudena, Ma, Acosta, Jesus Guillermo, Del Valle, Katia Perez, Fernandez-Lucas, Milagros, Garcia-Rubiales, Maria Antonia, Garcia-Herrera, Antonio Luis, Coll, Elisabeth, Merida, Evangelina, Castano, Itziar, Gil-Casares, Beatriz, Garro, Julia, Maduell, Francisco
• Format: Report
• Language: English
• Subjects: Albumin; Chronic kidney failure; Clinical trials; Colitis; Comparative analysis; Coronary heart disease; Health aspects; Morbidity; Mortality; Permeability; Spain; Stroke (Disease)
• ISSN: 2048-8505
• DOI: 10.1093/ckj/sfad128

Background. Dialysis patients have been maintaining a high rate of cardiovascular morbidity and mortality. For this reason, it is to introduce necessary new technical advances in clinical practice. There is a relation between toxins retention and inflammation, mortality and morbidity. Medium cut-off (MCO) membranes are a new generation of membranes that allow the removal of a greater number of medium-sized molecules compared with high-flux hemodialysis (HF-HD), but retaining albumin. MCO membranes have an increased permeability and the presence of internal filtration. Because of these special properties, MCO generated a new concept of therapy called expanded HD (HDx). Until now, online hemodiafiltration (OL-HDF) has demonstrated its superiority, in terms of survival, compared with HF-HD. However, the comparison between OL-HDF and HDx remains an unsolved question. Methods. The MOTheR HDx study trial (NCT03714386) is an open-label, multicenter, prospective, 1:1 randomized, parallel-group trial designed to evaluate the efficacy and safety of HDx compared with OL-HDF in patients treated for dialysis in Spain for up to 36 months. The main endpoint is to determinate whether HDx is non inferior to OL-HDF at reducing the combined outcome of all-cause death and stroke (ischemic or hemorrhagic), acute coronary syndrome (angina and myocardial infarction), peripheral arterial disease (amputation or revascularization) and ischemic colitis (mesenteric thrombosis). Results. The trial has already started. Even though hemodialysis is a renal replacement therapy that allows patients with end-stage renal disease to be kept alive, cardiovascular morbidity and mortality are very high. The dialysis membrane where the exchange of uremic toxins between the blood and the dialysis fluid occurs is the key element of the hemodialysis procedure. A new generation of membranes, called medium cut-off because they allow the removal of a greater number of medium-sized molecules, have generated a new concept of therapy called expanded HD. The objective of this study is to compare this new therapy with the technique that up to now has shown superiority in terms of survival, online hemodiafiltration. Keywords: cardiovascular events, expanded hemodialysis (HDx), medium cut-off membranes (MCO), mortality, online hemodiafiltration (OL-HDF)